Intech Biopharm Ltd - Asset Resilience Ratio

Latest as of March 2026: 6.12%

Intech Biopharm Ltd (6461) has an Asset Resilience Ratio of 6.12% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Intech Biopharm Ltd to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

NT$142.50 Million

≈ $4.49 Million USD Cash + Short-term Investments

Total Assets

NT$2.33 Billion

≈ $73.33 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Intech Biopharm Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Intech Biopharm Ltd asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down Intech Biopharm Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Intech Biopharm Ltd (6461) financial obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$142.50 Million	6.12%
Total Liquid Assets	NT$142.50 Million	6.12%

Asset Resilience Insights

Limited Liquidity: Intech Biopharm Ltd maintains only 6.12% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Intech Biopharm Ltd Industry Peers by Asset Resilience Ratio

Compare Intech Biopharm Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Aktis Oncology, Inc. Common stock NASDAQ:AKTS	Biotechnology	23.64%
Neurotech International Ltd AU:NTI	Biotechnology	0.22%
Sprint Bioscience AB ST:SPRINT	Biotechnology	77.81%
GT Biopharma Inc NASDAQ:GTBP	Biotechnology	0.00%
Herantis Pharma Oyj HE:HRTIS	Biotechnology	89.18%
Kura Oncology Inc NASDAQ:KURA	Biotechnology	76.35%
Sinocelltech Group Ltd SHG:688520	Biotechnology	5.27%
Generation Bio Co NASDAQ:GBIO	Biotechnology	55.52%

Annual Asset Resilience Ratio for Intech Biopharm Ltd (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Intech Biopharm Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	8.40%	NT$197.50 Million ≈ $6.22 Million	NT$2.35 Billion ≈ $74.07 Million	+5.90pp
2024-12-31	2.51%	NT$60.02 Million ≈ $1.89 Million	NT$2.40 Billion ≈ $75.48 Million	-16.69pp
2023-12-31	19.20%	NT$520.40 Million ≈ $16.40 Million	NT$2.71 Billion ≈ $85.41 Million	+7.04pp
2022-12-31	12.16%	NT$310.12 Million ≈ $9.77 Million	NT$2.55 Billion ≈ $80.35 Million	+7.74pp
2021-12-31	4.42%	NT$115.00 Million ≈ $3.62 Million	NT$2.60 Billion ≈ $81.97 Million	+0.61pp
2020-12-31	3.81%	NT$100.00 Million ≈ $3.15 Million	NT$2.62 Billion ≈ $82.59 Million	-0.22pp
2019-12-31	4.03%	NT$105.00 Million ≈ $3.31 Million	NT$2.61 Billion ≈ $82.09 Million	--

pp = percentage points

About Intech Biopharm Ltd

TWO:6461 Taiwan Biotechnology

Market Cap

$85.33 Million

NT$2.71 Billion TWD

Market Cap Rank

#19864 Global

#1141 in Taiwan

Share Price

NT$24.55

Change (1 day)

-0.20%

52-Week Range

NT$14.40 - NT$26.92

All Time High

NT$57.64